Nexgel, Inc · NASDAQ:NXGL
Nexgel — Investor Presentation (July 2025)
18 slides from Nexgel's investor presentation, Jul 31, 2025
Slide 1: Investor Presentation July 2025
Investor Presen 4 July 2025 @NEXCEL NASDAQ: NXGL |" /| f
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and
Slide 3: NEXGEL - Who We Are and What We Do
NEXGEL - Who We Are and What We Do @NEXCEL After two decades of creating custom hydrogel solutions for large medical device companies, our business today includes the development of patented medical devices, custom/white label products, and OTC healthcare consumer products. We invested in our in-hou
Slide 4: Multiple Products & Applications for Nexgel's Technology
Multiple Products & Applications for Nexgel’s Technology @NEXGEL Custom & Medical White Label Device NEXGEL is Bringing proven addressing the medical-grade importance of technology to skin integrity OTC and Beauty and overall & Cosmetics for skincare with a the first time medical device through many
Slide 5: Competitive Advantage: State-of-the-Art Manufacturing Facilities in NA
Competitive Advantage: 1 of 2 State-of-the-Art Manufacturing Facilities in NA Medical grade technology and facility, providing gels to multi-national device companies for over 20 years with sufficient capacity to fulfill consumer and healthcare segments 1 of 2 manufacturing facilities 16,500-square-
Slide 6: Converting and Packaging Facility
Converting and Packaging Facility 50% ownership in converting and packaging business in Granbury, Texas - Significant synergies which enable the onboarding of potential finished goods customers along with enhanced combined marketing and outreach efforts - Increased square footage and installed cutti
Slide 7: Hydrogels for Consumer and Medical Applications
Hydrogels for Consumer and Medical Applications * Electron beam technology eliminates the need for harmful chemicals in cross-linking, which, along with our paraben-free formulation, makes our patches the only option for many medical device applications and preferred among consumers * Gentle formula
Slide 8: Current Medical Device Pipeline
Current Medical Device Pipeline Addressing the importance of skin integrity and overall skincare with a medical device @NEXGEL NASDAQ: NXGL
Slide 9: Medical Device Pipeline: Drug Delivery
Medical Device Pipeline: Drug Delivery Potential for Multiple Drug Delivery Applications through Unique Hydrogel Technology Drug Delivery: Diclofenac Patch To treat short-term pain due to preclinical sprains and bruises Drug Delivery: Apremilast Patch ici daliaeihe HMiSinine eon ana one aii To treat
Slide 10: Consumer Health & Beauty
Consumer Health & Beauty Bringing proven medical-grade technology to OTC and B&C for the first time through many new consumer products & applications @NEXGEL NASDAQ: NXGL
Slide 11: NEXGEL Branded Products
NEXGEL Branded Products NOW PARABEN-FREE Fila Ewope HISTASOLV TURFGUARD @NEXGEL NASDAQ: NXGL
Slide 12: M&A Strategy: Consumer Brand Acquisition
M&A Strategy: Consumer Brand Acquisition Kenkoderm Skincare Line Silly George Beauty Brand * Acquisition completed in December 2023 * Acquisition completed in May 2024 * Complimentary line of alternative psoriasis treatments * Specialty eye and eyelash consumer product line Profitable (ttm) and imme
Slide 13: Cintas Corporation
Cintas Corporation Cintas is a leading provider of corporate identify uniforms, first aid and safety products and services to over 1 million businesses across North America * Cintas will distribute SilverSeal, NEXGEL's hospital-grade dressing for wounds and burns to its customers in many sectors inc
Slide 14: STADA Arzneimittel AG
STADA Arzneimittel AG Partnership with a leading European consumer health company accelerates the expansion of NEXGEL’s OTC product portfolio * STADA focuses on consumer healthcare products, generics and specialty pharm, selling products in approximately 120 countries across the world and this partn
Slide 15: AbbVie
AbbVie (NYSE: ABBV) CG Converting and Packaging is the exclusive supplier of gel pads to be used with AbbVie’s Rapid Acoustic Pulse device for the improvement in the appearance of cellulite + Allergan Aesthetics, acquired by AbbVie, purchased Soliton, the owner of the Resonic technology, for $550 mi
Slide 16: New Partnerships & Customers
New Partnerships & Customers Reducing Carcinogenic Plume in Laser Hair Removal a FDA-compliant IRB study conducted by Innovative Optics evaluating NEXGEL hydrogel's efficacy in reducing harmful plume during laser hair removal. * 30-patient trial at Florida Clinical Research Center. * Data publicatio
Slide 17: Revenue for Q1'25
Revenue for Q1'25 $3,000 $2,500 $2,000 $1,500 $1,000 $500 In millions $1.27M $1.08M +104% YOY +110% YOY Q4 2023 Q1 2024 $3.04M $2.94M +181% YOY +141% YOY $2.81M $1.44M +23% YOY TTM Revenue: $10.2M Q2 2024 Q3 2024 Q4 2024 Q1 2025 NASDAQ: NXGL +121% YOY Highlights: QI 2025 Revenue: $2.81 million, +121
Slide 18: Contact Us
Contact Us Investor Relations: KCSA Strategic Communications Valter Pinto, Managing Director PH: (212) 896-1254 NEXGEL@KCSA.com NASDAQ: NXGL